Human medicines European public assessment report (EPAR): Enwylma, denosumab, Date of authorisation: 26/06/2025, Revision: 2, Status: Authorised

EMA/PASS/0000287665

PSUSA/00010000/202601

Human medicines European public assessment report (EPAR): Zumrad, sasanlimab, Status: Application withdrawn

Annex to agenda of the CHMP meeting 14-17 September 2026

Agenda of the CHMP meeting 14-17 September 2026

Committee for Medicinal Products for Human Use (CHMP): 14-17 September 2026, European Medicines Agency, Amsterdam, the Netherlands, from 14 September 2026 to 17 September 2026

Human medicines European public assessment report (EPAR): Zonisamide Viatris (previously Zonisamide Mylan), zonisamide, Date of authorisation: 31/03/2016, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Zynlonta, loncastuximab tesirine, Date of authorisation: 20/12/2022, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Abrysvo, respiratory syncytial virus vaccine (bivalent, recombinant), Date of authorisation: 23/08/2023, Revision: 17, Status: Authorised